Subscribe to RSS
DOI: 10.1055/s-2002-33866
Chronische Hepatitis-C-Virusinfektion: immer behandeln! - Pro
Chronic hepatitis C virus infection: a general indication for treatment! - ProPublication History
eingereicht: 31.07.2002
akzeptiert: 21.08.2002
Publication Date:
05 September 2002 (online)

In der westlichen Welt sind 0,5-1,5 % der Bevölkerung chronisch mit dem Hepatitis C Virus (HCV) infiziert [1] . Trotz intensivierter Aufklärung in Laien- und Fachmedien sind in Deutschland wahrscheinlich weniger als 20 % der Infizierten diagnostiziert, d. h. die überwiegende Mehrheit der Betroffenen ist bislang nicht identifiziert.
Literatur
- 1
Zeuzem S, Roth W K, Herrmann G.
Virushepatitis
C.
Z Gastroenterol.
1995;
33
117-32
MissingFormLabel
- 2
Foster G R, Goldin R D, Thomas H C.
Chronic hepatitis C virus infection causes
a significant reduction in quality of life in the absence of cirrhosis.
Hepatology.
1998;
27
209-212
MissingFormLabel
- 3
Poynard T, Bedossa P, Opolon P. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups .
Natural
history of liver fibrosis progression in patients with chronic hepatitis
C.
Lancet.
1997;
349
825-832
MissingFormLabel
- 4
Colombo M.
Hepatitis
C virus and hepatocellular carcinoma.
Semin Liver Dis.
1999;
19
263-269
MissingFormLabel
- 5
El-Serag H B, Mason A C.
Rising incidence
of hepatocellular carcinoma in the United States.
N Engl
J Med.
1999;
340
745-750
MissingFormLabel
- 6
Sagmeister M, Renner E L, Mullhaupt B, Wong J B.
Simulation of
hepatitis C based on a mandatory reporting system.
Eur
J Gastroenterol Hepatol.
2002;
14
25-34
MissingFormLabel
- 7
Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns M P.
Treatment of
acute hepatitis C with interferon alfa-2b.
N Engl J Med.
2001;
345
1452-1457
MissingFormLabel
- 8
Falck-Ytter Y, Kale H, Mullen K D, Sarbah S A, Sorescu L, McCullough A J.
Surprisingly
small effect of antiviral treatment in patients with hepatitis C.
Ann
Intern Med.
2002;
136
288-292
MissingFormLabel
- 9
Hadziyannis S J, Cheinquer H, Morgan T, Diago M, Jensen D M, Sette H, Ramadori G, Bodenheimer H C, Marcellin P, Lee S -D, Roberts P J, Ackrill A M.
Peginterferon
alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy
and safety results from a phase III, randomized, double-blind, multicentre
study examining effect of duration of treatment and RBV dose.
J
Hepatol.
2002;
36 (Suppl 1)
3
MissingFormLabel
- 10
Manns M P, McHutchison J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D, Koury K, Ling M, Albrecht J K.
Peginterferon alfa-2b
plus ribavirin compared with interferon alfa-2b plus ribavirin for
initial treatment of chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
958-965
MissingFormLabel
- 11
Fried M W, Shiffman M L, Reddy R K. et al .
Pegylated (40 kDa) interferon alfa-2a
(Pegasys) in combination with ribavirin: efficacy and safety results
from a phase III, randomized, actively-controlled, multicenter study.
Gastroenterology.
2002;
120 (Suppl 1)
A55
MissingFormLabel
- 12
Camma C, Giunta M, Andreone P, Craxi A.
Interferon and prevention of
hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.
J
Hepatol.
2001;
34
593-602
MissingFormLabel
Prof. Dr. med. Stefan Zeuzem
Direktor der Klinik für Innere Medizin II, Universitätskliniken
des Saarlandes
66421 Homburg/Saar
Phone: 06841/16-23201
Fax: 06841/16-23267
Email: zeuzem@uniklinik-saarland.de